Patents by Inventor Ke Ding

Ke Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130124232
    Abstract: A business object model, which reflects data that is used during a given business transaction, is utilized to generate interfaces. This business object model facilitates commercial transactions by providing consistent interfaces that are suitable for use across industries, across businesses, and across different departments within a business during a business transaction. In some operations, software creates, updates, or otherwise processes information related to Indian employee payroll input, Indian social insurance arrangement, and Indian tax arrangement business objects.
    Type: Application
    Filed: June 12, 2010
    Publication date: May 16, 2013
    Inventors: Guoqing Zhao, Zhi Zhang, Haixing Zhou, Guy Cases Langhoff, Jesus Lopez Mijan, Karel Hol Soto Borja, Monica Reidl, Werner Gnan, Michael Seubert, Bin Fu, Rui Zhou, Gaogao Zheng, Xiaoming Wang, Debiao Cao, Ke Ding
  • Publication number: 20130030173
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Application
    Filed: September 13, 2012
    Publication date: January 31, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Ke Ding, Guoping Wang
  • Publication number: 20120101092
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Application
    Filed: December 23, 2011
    Publication date: April 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, Su Qiu, Guoping Wang, Dongguang Qin, Sanjeev Kumar
  • Patent number: 8144997
    Abstract: A method of processing an image includes the steps of receiving selection of the first region of interest (ROI) of an image, processing the first image data related to the first ROI, displaying the first image ROI based on the first image data, receiving selection of the second ROI of the image, which at least partially overlapping the first ROI, processing the second image data related to a portion of the second ROI that does not overlap the first ROI, combining the processed second image data with the processed first image data that overlaps the second ROI, and displaying the second image ROI based on the combined processed second image data and the processed first data.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: March 27, 2012
    Assignee: Marvell International Ltd.
    Inventor: Ke Ding
  • Patent number: 8088931
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: January 3, 2012
    Assignee: The Regents of the University of Michigan
    Inventors: Shaomeng Wang, Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, Su Qiu, Guoping Wang, Dongguang Qin, Sanjeev Kumar
  • Publication number: 20110218196
    Abstract: The compounds according to formula (VIII), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modulating estrogen related receptors (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity. The substituents of the formula are defined in the description.
    Type: Application
    Filed: March 6, 2009
    Publication date: September 8, 2011
    Inventors: Ke Ding, Chiwai Wong, Lijie Peng, Zhanfang Kang, Xi Zhou
  • Publication number: 20110071148
    Abstract: The compounds according to formula VIII, their pharmaceutically acceptable acid or base addition salts, and the uses thereof is disclosed. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for the preparing a medicament for modulating estrogen related receptor (ERR), and treating metabolic diseases, such as high blood fat, fatty liver, hyperglycemia, diabetes, obesity, etc. The definition of the groups of the formula is defined as the description.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 24, 2011
    Applicant: Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Ke Ding, Chiwai Wong, Zhanfang Kang, Xi Zhou
  • Publication number: 20100273799
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Application
    Filed: June 24, 2010
    Publication date: October 28, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, Su Qiu, Guoping Wang, Dongguang Qin, Sanjeev Kumar
  • Patent number: 7759383
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: July 20, 2010
    Assignee: The Regents of the University of Michigan
    Inventors: Shaomeng Wang, Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, Su Qiu, Guoping Wang, Dongguang Qin, Sanjeev Kumar
  • Publication number: 20060247305
    Abstract: The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death.
    Type: Application
    Filed: March 13, 2006
    Publication date: November 2, 2006
    Applicant: Regents of the University of Michigan
    Inventors: Shaomeng Wang, Ke Ding, Guozhi Tang, Zaneta Nikolovska-Coleska, Renxio Wang, Chao-Yie Yang
  • Publication number: 20060211757
    Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
    Type: Application
    Filed: February 22, 2006
    Publication date: September 21, 2006
    Applicant: Regents of the University of Michigan
    Inventors: Shaomeng Wang, Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, Su Qiu, Guoping Wang, Dongguang Qin, Sanjeev Kumar